Recent news coverage includes general market and sector developments but no direct company-specific updates. Historical news highlights include the company's share buyback program extension and insider share purchases.

• Earth Science Tech increased its share buyback authorization to $10 million and extended the plan by two years [N6].
• Insider purchases include a director buying 100,000 shares and the CEO purchasing 100,000 shares in early 2025 [N6].
• The company has been highlighted in analyst blogs and reports alongside other technology and healthcare companies [N6].

The company's vertical integration across compounding pharmacies, telemedicine, clinical support, and patient fulfillment creates operational synergies that can enhance patient experience and retention. Expansion of state licensure supports broader market access. Proprietary technology in consumer products offers diversification and potential for premium pricing. The robust share repurchase program and high insider ownership align management incentives with shareholder value. The company's focus on regulatory compliance and multi-channel marketing may support sustainable growth in competitive markets.

The company operates in highly competitive and fragmented markets with established players possessing greater financial resources. Regulatory compliance across multiple jurisdictions and sectors increases operational complexity and risk. Marketing effectiveness may be impacted by evolving privacy and healthcare laws. The consumer products segment faces competition from well-funded brands with larger marketing budgets. The company's relatively small scale and limited recent revenue disclosures may pose challenges in scaling operations and demonstrating consistent financial performance.

Earth Science Tech's competitive advantage stems from its vertical integration of healthcare services, linking telemedicine consultations directly with proprietary compounding pharmacy fulfillment. This integration allows for higher quality control and more responsive patient care compared to competitors relying on third-party pharmacies. Additionally, the company's proprietary magnetic heat-conduction technology in its MagneChef consumer products provides a unique value proposition in a saturated market. The company's disciplined capital allocation and significant insider ownership further support its strategic positioning.

• Regulatory Compliance Risk: The company operates in heavily regulated sectors including pharmaceutical compounding, telemedicine, clinical wellness, and consumer products, requiring adherence to complex federal, state, and local laws. Non-compliance could result in penalties and operational restructuring.
• Competitive Risk: ETST faces competition from large, well-established healthcare providers, traditional retailers, and digital health platforms with greater resources, which may limit its market share and growth.
• Marketing and Customer Acquisition Risk: The company's growth depends on effective marketing and customer retention strategies, which could be adversely affected by evolving privacy laws and healthcare regulations.
• Operational Complexity Risk: Managing diverse subsidiaries across healthcare, real estate, and consumer products increases operational complexity and may strain management resources.
• Financial Risk: The company may require additional capital to support growth, and access to such capital on acceptable terms is not guaranteed.

• Earth Science Tech, Inc. (ETST) is a diversified holding company focused on the health and wellness sector headquartered in Miami, Florida, redomiciled to Florida in 2022 [S1].
• The company operates a vertically integrated healthcare platform combining compounding pharmacy operations, telemedicine platforms, clinical support, and patient fulfillment [S1].
• Primary operating subsidiaries include RxCompoundStore.com, LLC (licensed compounding pharmacy in multiple states and Puerto Rico), Mister Meds, LLC (compounding pharmacy in Texas with sterile and hazardous drug handling capabilities), Peaks Curative LLC (telemedicine referral platform), DOConsultation.com LLC (telehealth focused on home-based therapies), Las Villas Health Care (brick-and-mortar healthcare facility), Avenvi LLC (real estate and asset management arm), and MagneChef (80%-owned direct-to-consumer kitchen products brand) [S1].
• The company has expanded state licensure to reach a near-national footprint for its pharmacy and telehealth services [S1].
• Avenvi LLC manages the company's real estate infrastructure and share repurchase program, operating under SEC Rule 10b-18 safe harbor provisions [S1].
• MagneChef leverages proprietary magnetic heat-conduction technology and operates in the direct-to-consumer kitchenware market with a digital-first marketing strategy [S1].
• The company emphasizes fiscal discipline, non-dilutive financing, reduction in authorized common stock, and a robust share buyback program, with management owning approximately 48% of outstanding shares [S1].
• Operations are subject to extensive federal, state, and local regulations governing pharmaceutical compounding, telemedicine, clinical wellness, real estate, and consumer products [S1].
• Pharmacy subsidiaries comply with Section 503A of the FDCA and USP standards (USP <795> and USP <797>) and maintain state licensure compliance [S1].
• Telemedicine operations comply with COVID-19 telemedicine flexibilities through December 31, 2026, and maintain separation between administrative support and licensed professionals' clinical judgment, with HIPAA-compliant data security [S1].
• Las Villas Health Care complies with state clinical licensure, health department standards, OSHA regulations, and language-access protocols [S1].
• Marketing strategies focus on digital acquisition, SEO, social media, and CRM systems to drive patient retention and brand loyalty across subsidiaries [S1].
• The company competes in highly fragmented and competitive markets including pharmaceutical compounding, telemedicine, clinical wellness, real estate asset management, and direct-to-consumer goods [S1].
• Competitive advantages include vertical integration linking clinical consultation with proprietary pharmacy fulfillment, and proprietary IP in consumer products [S1].
• As of March 31, 2026, the company had 77 employees with no union representation and good employee relations [S1].
• Financial snapshot as of June 30, 2026, shows cash and equivalents of $631,118, current assets of $5,088,193, current liabilities of $2,870,548, a current ratio of 1.77, and a cash ratio of 0.22 [S2].
• Net income for the quarter ended June 30, 2026, was $724,192 with basic and diluted EPS of $0.003 per share [S2].
• Revenue figure available from 2018 was $202,760, but no recent revenue data disclosed [S2].
• The company maintains a $10 million share repurchase program and has extended it by two years [N6].